0.80
+0.206(+34.92%)
Currency In USD
| Previous Close | 0.59 |
| Open | 0.61 |
| Day High | 1.49 |
| Day Low | 0.61 |
| 52-Week High | 4.65 |
| 52-Week Low | 0.55 |
| Volume | 109.26M |
| Average Volume | 165,290 |
| Market Cap | 5.57M |
| PE | -0.38 |
| EPS | -2.12 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 1.45 |
| Change | 0.21 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $1.94 as of January 31, 2026 at a share price of $0.796. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 4 years ago, it would be worth $6.89 as of January 31, 2026 at a share price of $0.796.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
GlobeNewswire Inc.
Jan 29, 2026 1:27 PM GMT
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan has been achieved at the 150 mg dose, with 220 mg co
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jan 29, 2026 1:25 PM GMT
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities wh
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
GlobeNewswire Inc.
Dec 18, 2025 1:30 PM GMT
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimiz